Moreno-Sánchez Teresa, Moreno-Ramírez Manuela, Machancoses Francisco H
UGC Image Diagnostics, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain.
Centro Diálisis Avericum, Cádiz, Spain.
J Vasc Access. 2025 Jul;26(4):1337-1347. doi: 10.1177/11297298241272259. Epub 2024 Sep 11.
To compare primary patency after angioplasty with drug-coated balloon (DCB)-Passeo-18Lux, BIOTRONIK versus uncoated balloon in dysfunctional peripheral vascular access (PVA) for hemodialysis.
A total of 133 patients from four hospitals were randomized to receive DCB or plain old balloon angioplasty (POBA) after satisfactory treatment (residual stenosis <30%) with high pressure balloon (HPB). The primary endpoint was clinical patency of PVA 2 years after angioplasty. Secondary endpoints included the relationship between the location of stenosis and patency and also, other covariates. Mortality at 2 years was compared between both groups.
Patency measured in days after angioplasty was higher in fistulae dilated with DCB than HPB. Kaplan-Meier survival curves showed the next percent of success (free time restenosis) after DCB versus POBA at 6 months-77.1% versus 58.2% (160.41-143.72 days until restenosis), 12 months-51.4% versus 44.3% (274.1-237.23), 18 months-38.6% versus 38% (350.74-305.18), and 24 months-37.1% versus 30.4% (419.04-369.1). At 6 months, this difference was statistically significant ( = 0.018), but not at 12 ( = 0.225), 18 ( = 0.471), or 24 months ( = 0.236). Mortality was similar in both groups.
DCB angioplasty resulted in superior target lesion primary patency (TLPP)-free survival at 6 months of follow-up. No significant improvements in TLPP-free survival long term were observed. Mortality observed at 1 and 2 years was similar in DCB and POBA: there was no significant difference, and a safety study demonstrated no difference between the two groups (complications and mortality): DCB is safe to use in stenosis treatment in patients who are PVA carriers.
Level Ia, therapeutic study, RCT. EBM ratings will be based on a scale of 1-5.
比较使用百多力(BIOTRONIK)的药物涂层球囊(DCB)Passeo - 18Lux进行血管成形术后与未涂层球囊在功能失调的外周血管通路(PVA)用于血液透析时的初始通畅率。
来自四家医院的133例患者在经高压球囊(HPB)进行满意治疗(残余狭窄<30%)后,随机接受DCB或普通球囊血管成形术(POBA)。主要终点是血管成形术后2年PVA的临床通畅率。次要终点包括狭窄部位与通畅率之间的关系以及其他协变量。比较两组2年时的死亡率。
用DCB扩张的瘘管血管成形术后以天数衡量的通畅率高于HPB。Kaplan - Meier生存曲线显示,DCB与POBA相比,6个月时的成功百分比(无再狭窄时间)分别为77.1%对58.2%(直至再狭窄的天数为160.41 - 143.72天),12个月时为51.4%对44.3%(274.1 - 237.23天),18个月时为38.6%对38%(350.74 - 305.18天),24个月时为37.1%对30.4%(419.04 - 369.1天)。在6个月时,这种差异具有统计学意义(P = 0.018),但在12个月(P = 0.225)、18个月(P = 0.471)或24个月(P = 0.236)时无统计学意义。两组的死亡率相似。
DCB血管成形术在随访6个月时导致更好的靶病变初始通畅率(TLPP) - 无复发生存率。长期未观察到TLPP - 无复发生存率有显著改善。DCB组和POBA组在1年和2年时观察到的死亡率相似:无显著差异,一项安全性研究表明两组之间无差异(并发症和死亡率):DCB用于PVA患者的狭窄治疗是安全的。
Ia级,治疗性研究,随机对照试验。循证医学评级将基于1 - 5级量表。